Physician profile
Mark Anthony Gruszynski
NPI 1396188033
$3,944.74
in general payments reported to CMS, 2019-2025
20 companies · $342 in 2025
The $342 reported for 2025 was less than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $609 · 2021: $1,051 · 2022: $1,434 · 2023: $379 · 2024: $130 · 2025: $342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Musculoskeletal Transplant Foundation INC. | $848.47 | 2020-2021 | |
| Sientra, INC. | $563.82 | 2020-2023 | Sientra High Strength Cohesive Silicone Gel Breast Implant |
| Davol INC. | $542.81 | 2022-2025 | Phasix Mesh |
| Galderma Laboratories, L.P. | $294.46 | 2021-2022 | |
| Allergan, INC. | $287.09 | 2020-2022 | |
| Trice Medical, INC. | $267.46 | 2021 | |
| Mentor Worldwide LLC | $197.59 | 2021-2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Stryker Corporation | $197.01 | 2021 | |
| Sanara Medtech INC. | $139.72 | 2025 | Celleraterx |
| Revance Therapeutics, INC. | $129.82 | 2024 | Daxxify |
| Sun Pharmaceutical Industries INC. | $90.49 | 2022-2023 | Blu-U, Odomzo |
| Dilon Technologies, INC. | $90.37 | 2023 | Hemoblast Bellows |
| Axogen | $75.94 | 2020 | |
| Genzyme Corporation | $54.86 | 2025 | |
| Organogenesis INC. | $50.21 | 2023 | Puraply |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $34.07 | 2021 | |
| Amgen INC. | $25.47 | 2023 | Enbrel, Otezla |
| Surgenex LLC | $25.00 | 2025 | Pellograft, Surmatrix, Surgraft |
| Helsinn Therapeutics (U.S.), INC. | $17.08 | 2023 | Valchlor |
| Sandoz INC. | $13.00 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gruszynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.